Delving into the real-world efficacy and safety of fecal microbiota or Rebyota outlined by Paul Feuerstadt, MD, paints a considerably reassuring picture of this therapeutic agent in dealing with recurrent C difficile. Rebyota has enjoyed FDA approval for over two years, and Dr. Feuerstadt, associate clinical professor of Medicine at Yale School of Medicine, who…